Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rheumatoid arthritis and the complement system.

Marcin Okroj1, Dick Heinegård, Rikard Holmdahl

  • 1Lund University, Department of Laboratory Medicine, University Hospital Malmö, Malmö, Sweden.

Annals of Medicine
|September 14, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Type 2 and type 1 diabetes have opposing effects on the systemic murine complement alternative pathway.

iScience·2026
Same author

C4BP occludes the non-opsonic interaction of <i>Neisseria gonorrhoeae</i> with human neutrophil CEACAMs.

Infection and immunity·2026
Same author

Selection of laboratory assays for reliable assessment of complement-dependent cytotoxicity: impact of assay choice on CDC quantification.

Frontiers in immunology·2026
Same author

COMP-PMEPA1 axis promotes epithelial-to-mesenchymal transition in breast cancer cells.

Molecular oncology·2026
Same author

C4BP occludes the non-opsonic interaction of <i>Neisseria gonorrhoeae</i> with human neutrophil CEACAMs.

bioRxiv : the preprint server for biology·2026
Same author

Nuclear cell-free DNA on the loose: an early warning signal of ischemia-reperfusion injury in kidney transplantation.

Frontiers in immunology·2026
Same journal

Integrative profiling of oral fungal communities across <i>Mycobacterium Tuberculosis</i> burden groups in Xpert-positive patients.

Annals of medicine·2026
Same journal

Prevalence and determinants of alcohol use disorder and its association with adherence to antihypertensive therapy among adult hypertensive patients in a hospital setting, Northwest Ethiopia.

Annals of medicine·2026
Same journal

Early detection of severe fetal growth restriction using multimodal deep learning based on ultrasound and prenatal biomarkers.

Annals of medicine·2026
Same journal

Tinnitus, hyperacusis and somatic complaints in a diverse Norwegian clinical population: implications for assessment and rehabilitation.

Annals of medicine·2026
Same journal

Epidemiological analysis of acute poisoning cases based on Poison control center data from 2021 to 2024.

Annals of medicine·2026
Same journal

Pediatric nurses' stress and their knowledge, attitudes, and practices towards first-aid for pediatric trauma: a latent profile analysis.

Annals of medicine·2026
See all related articles

Complement activation, involving both classical and alternative pathways, drives rheumatoid arthritis (RA) pathology. Targeting complement, particularly C5a, shows therapeutic promise for RA treatment.

Area of Science:

  • Immunology
  • Rheumatology

Background:

  • Complement activation plays a role in autoimmune and inflammatory diseases like rheumatoid arthritis (RA).
  • Understanding complement's contribution to RA pathogenesis is crucial for developing targeted therapies.

Purpose of the Study:

  • To review the current knowledge on complement's role in rheumatoid arthritis.
  • To elucidate the molecular mechanisms of complement activation in RA using clinical, animal, and in vitro data.

Main Methods:

  • Review of clinical observations in RA patients.
  • Analysis of in vivo animal models for RA.
  • In vitro experiments to understand molecular mechanisms.

Main Results:

  • Both classical and alternative complement pathways are pathologically activated in RA.

Related Experiment Videos

  • Triggers include autoantibodies, dying cells, and cartilage proteins like fibromodulin.
  • Anaphylatoxin C5a is a key mediator of tissue damage, with C3b and membrane attack complex also contributing.

    • Conclusions:

    • Complement activation is a significant factor in RA pathogenesis.
    • Experimental complement inhibition strategies are promising for human RA treatment.